7,690 Shares in ANI Pharmaceuticals, Inc. $ANIP Bought by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,690 shares of the specialty pharmaceutical company’s stock, valued at approximately $704,000.

A number of other institutional investors have also bought and sold shares of the company. Global Alpha Capital Management Ltd. lifted its stake in shares of ANI Pharmaceuticals by 17.2% in the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock valued at $56,251,000 after purchasing an additional 126,500 shares during the period. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares in the last quarter. Mizuho Markets Americas LLC increased its holdings in ANI Pharmaceuticals by 7.8% in the second quarter. Mizuho Markets Americas LLC now owns 212,830 shares of the specialty pharmaceutical company’s stock worth $13,887,000 after purchasing an additional 15,357 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in ANI Pharmaceuticals by 6.4% in the second quarter. Loomis Sayles & Co. L P now owns 206,382 shares of the specialty pharmaceutical company’s stock valued at $13,466,000 after buying an additional 12,494 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of ANI Pharmaceuticals by 32.0% during the 2nd quarter. Bank of America Corp DE now owns 185,465 shares of the specialty pharmaceutical company’s stock worth $12,102,000 after buying an additional 44,916 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 target price for the company. Guggenheim upped their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $80.00 on Tuesday. The company has a market capitalization of $1.80 billion, a P/E ratio of 49.08 and a beta of 0.50. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. ANI Pharmaceuticals, Inc. has a 52-week low of $54.10 and a 52-week high of $99.50. The business has a 50-day simple moving average of $81.88 and a two-hundred day simple moving average of $85.30.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The company had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same quarter last year, the company earned $1.34 earnings per share. The company’s revenue for the quarter was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Transactions at ANI Pharmaceuticals

In other news, Director Patrick D. Walsh sold 8,643 shares of the stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $86.88, for a total value of $750,903.84. Following the completion of the sale, the director owned 61,405 shares in the company, valued at $5,334,866.40. This represents a 12.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Meredith Cook sold 500 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total transaction of $42,165.00. Following the transaction, the vice president owned 74,374 shares in the company, valued at approximately $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 28,101 shares of company stock worth $2,453,063. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.